Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal DementiaGlobeNewsWire • 07/28/20
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal DementiaGlobeNewsWire • 07/24/20
Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International ConferenceGlobeNewsWire • 07/21/20
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in ChinaGlobeNewsWire • 03/25/20
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of DirectorsGlobeNewsWire • 03/23/20
Alector (ALEC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 03/17/20
Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?Zacks Investment Research • 03/11/20
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal DementiaGlobeNewsWire • 02/05/20
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/03/20
Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public OfferingGlobeNewsWire • 01/31/20
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative DiseasesGlobeNewsWire • 01/06/20
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr.GlobeNewsWire • 12/13/19